Boehringer Ingelheim to partner with Weill to find new COPD treatments

Boehringer Ingelheim has revealed that it will be collaborating with Weill Cornell Medicine to explore new treatments for chronic obstructive pulmonary disease (COPD).

The two organisations are set to work together to investigate potential new options for halting progress of the life-threatening respiratory disease and will even be exploring whether or not its onset can be biologically reversed with specially-designed drugs.

Boehringer and Weill have entered into a three-year partnership, which will combine the former's expertise in developing treatments for respiratory illnesses with the latter's knowledge of chronic airway diseases and how they develop over time.

Currently, patients with COPD are encouraged to stay as active as possible in order to improve their lung function, but the disease is ultimately untreatable; however, Boehringer and Weill believe otherwise.

Dr Clive R Wood, senior corporate vice-president of discovery research at Boehringer Ingelheim, commented: "The new collaboration is an excellent example of our unique partnering approach and our focus on early innovation, underscoring our ambition to develop the next generation of medical treatments for patients with COPD."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

Image: shironosov via iStock